Fig. 2
iRFA promotes tumor progression and hinders anti-PD-1 therapy. a. Diagram of iRFA treatment. 1 × 106 CT26 or MC38 cells were injected i.d. into male BALB/C and C57BL/6 mice, respectively, on right flank. iRFA was performed to cause partial necrosis of the tumors when the longest dimension reach about 0.8 cm. b Growth curve of the residual tumor (n = 10). c. Weight of the residual tumor examined on day 14 after iRFA by dissection the mice (n = 10). d Number of the metastasis examined on day 14 after iRFA by dissection the mice (n = 10). e Kaplan–Meier survival curves are shown and the log-rank test was performed (n = 10). f Schematic of the study of combined therapy with iRFA and PD-1 inhibition. Anti-PD-1 mAb (200 μg, clone: J43) or vehicle was administered through intraperitoneal injection to mice every 3 days for a total of four times. g Growth curve of the residual tumor (one-sided ANOVA test, ns presents not significant, ***P < 0.001, n = 10). h Weight of the residual tumor examined on day 14 after iRFA by dissection the mice. i Number of metastasis examined on day 14 (n = 10). j Kaplan–Meier survival curves are shown and the log-rank test was performed (ns presents not significant: compared to iRFA + vehicle, ***P < 0.001: compared to the other three groups, n = 10). Data represent cumulative results from 1/2 independent experiments with 10 mice per group. Statistical differences between pairs of groups were determined by a two-tailed Student’s t-test. (ns presents not significant, *P < 0.05, **P < 0.01 ***P < 0.001). Each error bar represents means ± SEM. Source data are provided as a Source Data file.
